TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00866502

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continous ICV infusion
Study: NCT01393314

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Honeywell HomMed Telemonitor
Description: telemonitoring post hospitalization
Study: NCT04593641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P59
Description: administered
Study: NCT03279757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTC 15 minutes
Description: Topical application of LTC with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTC 25 minutes
Description: Topical application of LTC with 25 minutes application time After 25 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional CO2 laser, 50 mJ, 5% density
Description: Pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Study: NCT00661141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: oral dose of ethanol (0.5 g/kg)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: oral dose of ethanol (0.5 g/kg)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: oral dose of ethanol (0.5 g/kg)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: oral dose of ethanol (0.5 g/kg)
Study: NCT03279757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional CO2 laser, 50 mJ, 5% density
Description: Pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Study: NCT01909934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin IV infusion
Study: NCT02814318

Intervention type: BIOLOGICAL
Intervention: Vaginal and rectovaginal swab cultures
Description: The only intervention that will occur in this study is obtaining vaginal and recto-vaginal swab cultures upon admission to the labor and delivery room and every two hours to follow until 8 hours after administration of IV vancomycin or IV penicillin.

Intervention type: BIOLOGICAL
Intervention: Vaginal and rectovaginal swab cultures
Description: The only intervention that will occur in this study is obtaining vaginal and recto-vaginal swab cultures upon admission to the labor and delivery room and every two hours to follow until 8 hours after administration of IV vancomycin or IV penicillin.
Study: NCT01811550

Intervention type: OTHER
Intervention: Glycemic Control
Study: NCT03279757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional CO2 laser, 50 mJ, 5% density
Description: Pain stimulus with the fractional CO2 laser, 50 mJ, 5% density

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional CO2 laser, 50 mJ, 5% density
Description: Pain stimulus with the fractional CO2 laser, 50 mJ, 5% density

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional CO2 laser, 50 mJ, 5% density
Description: Pain stimulus with the fractional CO2 laser, 50 mJ, 5% density

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional CO2 laser, 50 mJ, 5% density
Description: Pain stimulus with the fractional CO2 laser, 50 mJ, 5% density

Intervention type: DEVICE
Group type: OTHER
Intervention: fractional CO2 laser, 50 mJ, 5% density
Description: Pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Study: NCT03919422

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T2 paravertebral block
Description: Ultrasound guided T2 thoracic paravertebral block is added in ICTP group. After interscalene brachial plexus block and superficial cervical plexus block have been administrated, selective 2nd thoracic nerve root(T2) will be blocked with 10 ml of 0.25% ropivacaine(naropin).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interscalene brachial plexus block and superficial cervical plexus block
Description: An ultrasound-guided IC block using an ultrasound machine (Sonosite, USA), and an linear array probe with a sterile cover and a 22G(Gauge) block needle is performed. An in-plane approach, advancing the needle along the longitudinal axis of the ultrasound transducer and visualizing the entire shaft is employed. Twenty ml of 0.375% ropivacaine(naropin) is injected around brachial plexus and 10 ml of 0.25% ropivacaine around superficial cervical plexus.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interscalene brachial plexus block and superficial cervical plexus block
Description: An ultrasound-guided IC block using an ultrasound machine (Sonosite, USA), and an linear array probe with a sterile cover and a 22G(Gauge) block needle is performed. An in-plane approach, advancing the needle along the longitudinal axis of the ultrasound transducer and visualizing the entire shaft is employed. Twenty ml of 0.375% ropivacaine(naropin) is injected around brachial plexus and 10 ml of 0.25% ropivacaine around superficial cervical plexus.
Study: NCT01233791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Diazepam Suppository
Description: 10mg compounded vaginal suppository

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Suppository
Description: Patients will be asked to use one vaginal suppository every night for 28 days
Study: NCT03655353

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ABY-PET
Description: Diagnostic PET for HER2 expression
Study: NCT03591068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: OPN-375 186 μg BID, Delivered via exhalation delivery system
Study: NCT00554515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD IL2
Study: NCT02491840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsy of Gastric and cardia adenocarcinomas
Study: NCT01326104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTRNA-xALT
Description: TTRNA-xALT 3 x 10\^7/kg by intravenous injection once.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTRNA-xALT
Description: TTRNA-xALT 3 x 10\^7/kg by intravenous injection once.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTRNA-DCs
Description: TTRNA-DCs 1 x 10\^7 by intradermal injection every 2 weeks for 3 total doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTRNA-DCs
Description: TTRNA-DCs 1 x 10\^7 by intradermal injection every 2 weeks for 3 total doses.
Study: NCT00833638

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet orally daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tadalafil
Description: Orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Orally once daily
Study: NCT03371420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-AD

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET Scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Draws
Study: NCT00307827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visilizumab
Description: Visilizumab administered intravenously once per day for two days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visilizumab
Description: Visilizumab administered intravenously once per day for two days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visilizumab
Description: Visilizumab administered intravenously once per day for two days
Study: NCT01178086

Intervention type: DRUG
Intervention: Rituximab
Description: Rituximab IV
Study: NCT02348073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vayarin®, supplementation of n-3 PUFA
Description: Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.~At the end of this period, active product will be continued, at the same dose, for a 12 week-open label period. All patients will be administered the active product.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.
Study: NCT03977220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel combined with S-1
Description: Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
Study: NCT00596440

Intervention type: DRUG
Intervention: Transdermal nicotine patch
Description: 8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg.

Intervention type: DRUG
Intervention: Transdermal nicotine patch
Description: 8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg.
Study: NCT03969719

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835919
Description: 150 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835919
Description: 300 mg once daily
Study: NCT03838042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and Entinostat
Description: Patients entering phase I will receive one week entinostat without nivolumab (priming phase) before receiving the combination treatment of nivolumab and entinostat.
Study: NCT01166633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin
Description: pitavastatin 2mg per daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatin 10mg per daily
Study: NCT02130193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin
Description: Danirixin is available as 50 or 75 mg white, film coated immediate release tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin
Description: Danirixin is available as 50 or 75 mg white, film coated immediate release tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive danirixin matching placebo
Study: NCT01248338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol succinate
Description: once daily 50 or 100 mg for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: once daily 5 mg capsule for one year
Study: NCT01142206

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary
Description: All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary
Description: All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: All participants will receive a physical activity goal of 200 minutes/week of moderate-intense physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: All participants will receive a physical activity goal of 200 minutes/week of moderate-intense physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV Watching + Physical Activity
Description: The TV Watching + physical activity arm will receive a TV watching goal of watching less than 10 hours of TV/week.
Study: NCT01667432

Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a commercial product (PEGASYS®) was supplied as a solution in prefilled syringes.
Study: NCT03276676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FLT
Description: PET exams of \[18F\]FLT will be acquired in each patient at up to three time points: (1) prior to any tumor-directed therapy, either prior to surgery or immediately after surgery providing a complete surgical resection was not performed and confirmed by a post-operative contrast MRI scan where residual tumor \> 1.0 cm in diameter was present and prior to any tumor-directed therapy; (2) at the conclusions of the initial (\~6-8 weeks) chemoradiotherapy; and (3) patients with MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FLT
Description: PET exams of \[18F\]FLT will be acquired in each patient at up to three time points: (1) prior to any tumor-directed therapy, either prior to surgery or immediately after surgery providing a complete surgical resection was not performed and confirmed by a post-operative contrast MRI scan where residual tumor \> 1.0 cm in diameter was present and prior to any tumor-directed therapy; (2) at the conclusions of the initial (\~6-8 weeks) chemoradiotherapy; and (3) patients with MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Fluciclovine
Description: PET exams of \[18F\]Fluciclovine will be acquired in each patient at up to three time points: (1) prior to any tumor-directed therapy, either prior to surgery or immediately after surgery providing a complete surgical resection was not performed and confirmed by a post-operative contrast MRI scan where residual tumor \> 1.0 cm in diameter was present and prior to any tumor-directed therapy; (2) at the conclusions of the initial (\~6-8 weeks) chemoradiotherapy; and (3) patients with MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Fluciclovine
Description: PET exams of \[18F\]Fluciclovine will be acquired in each patient at up to three time points: (1) prior to any tumor-directed therapy, either prior to surgery or immediately after surgery providing a complete surgical resection was not performed and confirmed by a post-operative contrast MRI scan where residual tumor \> 1.0 cm in diameter was present and prior to any tumor-directed therapy; (2) at the conclusions of the initial (\~6-8 weeks) chemoradiotherapy; and (3) patients with MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiation.
Study: NCT02246140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebral MRI and MRA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cerebral MRI and MRA
Study: NCT01864564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Screen
Description: Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.
Study: NCT02269670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given PO
Study: NCT02269670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Given IM or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: megestrol acetate
Description: Given PO
Study: NCT03356925

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Xpert Ultra Point of Care testing
Description: The intervention is the point of care Xpert Ultra TB diagnostic compared to the standard of care centralised TB testing at a centralised facility
Study: NCT01667601

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Care
Description: Psychiatric outpatient care provided by the outpatient departments, e.g., medical consultation, brief education by psychiatric nurses and financial advices or referrals by social workers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based program
Description: The program was based on the psychoeducation programs by Chien et al and Lehman et al, as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn(1990).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness-based program
Description: The program was based on the psychoeducation programs by Chien et al and Lehman et al, as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn(1990).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation group
Description: A 5-month patient psychoeducation group program (12 sessions) led by the research team will be provided.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychoeducation group
Description: A 5-month patient psychoeducation group program (12 sessions) led by the research team will be provided.
Study: NCT00234065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: oral tablet, 100 mg twice a day and placebo of aspirin once a day, 1 to 5years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: oral tablet, placebo of cilostazol twice a day and 81 mg once a day, 1 to 5 years
Study: NCT02889991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Dry Needling
Description: This technique follows the criteria established by Dr Hong C-Z. This technique is known as fast in and fast out technique and uses repeated insertion of the acupuncture needle in the myofascial trigger point, with the aim to get multiple local twitch responses. The technique ends when the local twitch responses disappear.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low intensity Dry Needling
Description: Technique proposed by the main investigator and based on the studies of Professor Dr. Jay P. Shah and the mechanisms of neuromodulation that transmits us the acupuncture scientific evidence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascial Mechanotransduction Dry Needling
Description: The Fascial Mechanotransduction Dry Needling Technique, strikes with the acupuncture needle until it reaches and pierces the myofascial trigger point. Then the acupuncture needle is rolled in the connective tissue, which causes an intense coupler that we define as needle grasp. Finally, the acupuncture needling is pulled-out twice.~The screwing and the two pull-out of the acupuncture needle is performed in the infraspinatus and supraspinatus muscles and we describe it as mechanotransduction cycle. Each cycle lasts 30 seconds and the whole technique lasts 3 minutes per session.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Technique Placebo of Dry Needling
Description: Technique with a total duration of 3 minutes per session:~* To locate the myofascial trigger points of infraspinatus and supraspinatus muscles and put each bridle on them.~* Monitor longitudinally taut band, with index and middle fingers.~* Percuss with tube and needle placebo (Sham needle) on Infraspinatus.~* Remove the tube and needle placebo from the device. Reintroducing the placebo needle into the tube and strike on the supraspinatus. Repeat this sequence without interruption for 3 minutes.~* Remove the bridles and perform hemostasis with cotton.~* We will give end to the technique placebo of dry needling.
Study: NCT03334617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab given IV at 1500 mg Q4W ±2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab given IV at 1500 mg Q4W ±2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab given IV at 1500 mg Q4W ±2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab given IV at 1500 mg Q4W ±2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab given IV at 1500 mg Q4W ±2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab given IV at 1500 mg Q4W ±2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab given IV at 1500 mg Q4W ±2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150
Description: AZD9150 given IV at 200mg every other day of a 1-week lead-in period followed by QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: AZD6738 given orally at 240mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vistusertib
Description: Vistusertib (AZD2014) given orally at a dose of 125 mg BD on an intermittent dosing schedule of 2 days on, 5 days off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib (AZD2281) given orally at 300 mg BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab given at dose level 1 for 2 cycles and then dose level 2 thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab deruxtecan
Description: Durvalumab given IV at 1120mg Q3W ±2 days for Module 6 only \& trastuzumab deruxtecan given at 5.4 mg/kg via IV infusion Q3W ±2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib
Description: cediranib given orally at 20 mg tablets on an intermittent schedule (5 days on, 2 days off), starting on C1D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738 (ceralasertib)
Description: AZD6738 given at 240 mg twice daily for 14 days on treatment in each 28-day cycle, between Days 1 and 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738 (ceralasertib)
Description: AZD6738 given orally at 240mg twice daily for 14 days in each 28 day cycle (starting from Cycle 1) between Days 15-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738 (ceralasertib) (240 mg or 160 mg)
Description: AZD6738 given orally at 240mg or 160mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738 (ceralasertib) 7 days monotherapy
Description: AZD6738 given orally at 240 mg twice daily for 7 days on Day 1-7 in each 28 day cycle
Study: NCT03195010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Transfusion
Description: Undergo lower dose platelet transfusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Transfusion
Description: Undergo higher dose platelet transfusion